11
TITLE: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
AUTHORS: Dorado, P; Berecz, R; Penas Lledo, EM; Caceres, MC; LLerena, A;
PUBLISHED: 2006, SOURCE: CURRENT DRUG TARGETS, VOLUME: 7, ISSUE: 12
INDEXED IN: Scopus WOS CrossRef
12
TITLE: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
AUTHORS: Dorado, P; Caceres, MC; Pozo Guisado, E; Wong, ML; Licinio, J; Llerena, A;
PUBLISHED: 2005, SOURCE: BIOTECHNIQUES, VOLUME: 39, ISSUE: 4
INDEXED IN: WOS CrossRef
13
TITLE: Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship  Full Text
AUTHORS: Dorado, P; Berecz, R; Caceres, MC; Gonzalez, I; Cobaleda, J; Llerena, A;
PUBLISHED: 2005, SOURCE: CLINICAL CHEMISTRY AND LABORATORY MEDICINE, VOLUME: 43, ISSUE: 3
INDEXED IN: Scopus WOS CrossRef
14
TITLE: The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
AUTHORS: Berecz, R; Dorado, P; De La Rubia, A; Caceres, MC; Degrell, I; LLerena, A;
PUBLISHED: 2004, SOURCE: CURRENT DRUG TARGETS, VOLUME: 5, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef
15
TITLE: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
AUTHORS: Llerena, A; Berecz, R; Dorado, P; de la Rubia, A;
PUBLISHED: 2004, SOURCE: JOURNAL OF PSYCHOPHARMACOLOGY, VOLUME: 18, ISSUE: 2
INDEXED IN: Scopus WOS CrossRef
16
TITLE: Relationship between haloperidol plasma concentration, Debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients
AUTHORS: Llerena, A; de la Rubia, AC; Berecz, R; Dorado, P;
PUBLISHED: 2004, SOURCE: PHARMACOPSYCHIATRY, VOLUME: 37, ISSUE: 2
INDEXED IN: Scopus WOS CrossRef: 13
17
TITLE: Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions  Full Text
AUTHORS: LLerena, A; Dorado, P; Berecz, R; Gonzalez, AP; Penas LLedo, EM;
PUBLISHED: 2004, SOURCE: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, VOLUME: 59, ISSUE: 12
INDEXED IN: Scopus WOS
18
TITLE: Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions  Full Text
AUTHORS: Pedro Dorado; Roland Berecz; Antonio P Gonz�lez; Eva M Pe�as-LLed�; Adri�n LLerena;
PUBLISHED: 2004, SOURCE: European Journal of Clinical Pharmacology, VOLUME: 59, ISSUE: 12
INDEXED IN: CrossRef
19
TITLE: Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios  Full Text
AUTHORS: Dorado, P; Berecz, R; Caceres, MC; Llerena, A;
PUBLISHED: 2003, SOURCE: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, VOLUME: 789, ISSUE: 2
INDEXED IN: Scopus WOS CrossRef
20
TITLE: Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype  Full Text
AUTHORS: Berecz, R; de la Rubia, A; Dorado, P; Fernandez Salguero, P; Dahl, ML; Llerena, A;
PUBLISHED: 2003, SOURCE: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, VOLUME: 59, ISSUE: 1
INDEXED IN: Scopus WOS
Page 2 of 2. Total results: 20.